Full metadata record

DC Field Value Language
dc.contributor.authorDoo Sun Sim-
dc.contributor.authorMyung Ho Jeong-
dc.contributor.authorHyo Soo Kim-
dc.contributor.authorHyeon Cheol Gwon-
dc.contributor.authorKi Bae Seung-
dc.contributor.authorSeung Woon Rha-
dc.contributor.authorShung Chull Chae-
dc.contributor.authorChong Jin Kim-
dc.contributor.authorKwang Soo Cha-
dc.contributor.authorJong Seon Park-
dc.contributor.authorJung Han Yoon-
dc.contributor.authorJei Keon Chae-
dc.contributor.authorSeung Jae Joo-
dc.contributor.authorDong Ju Choi-
dc.contributor.authorSeung Ho Hur-
dc.contributor.authorIn Whan Seong-
dc.contributor.authorMyeong Chan Cho-
dc.contributor.authorDoo Il Kim-
dc.contributor.authorSeok Kyu Oh-
dc.contributor.authorTae Hoon Ahn-
dc.contributor.authorJin Yong Hwang-
dc.date.accessioned2019-12-27T16:30:46Z-
dc.date.available2019-12-27T16:30:46Z-
dc.date.issued2020-
dc.identifier.citationJournal of cardiology, Vol.75(1) : 66-73, 2020-
dc.identifier.issn1876-4738-
dc.identifier.otheroak-2019-0330-
dc.identifier.urihttp://kumel.medlib.dsmc.or.kr/handle/2015.oak/42354-
dc.description.abstractBackground: The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome remains uncertain. This study investigated the benefit of DAPT beyond 12 months after drug-eluting stents (DES) for acute myocardial infarction (MI). Methods: From Korea Acute Myocardial Infarction Registry-National Institute of Health database, 6199 patients treated with DAPT for 12 months after DES (second-generation DES 98%) without ischemic or bleeding events were analyzed. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death from any cause, MI, or ischemic stroke during the period from 12 to 24 months. Results: After adjustment using inverse probability of treatment weighting, patients who received DAPT beyond 12 months ( n = 4795), compared to patients treated with 12-month DAPT ( n = 1404), had a similar incidence of MACCE (1.3% vs. 1.0%, HR: 1.32, 95% CI: 0.71–2.45, p = 0.378). The 2 groups did not differ significantly in the rates of death (0.1% vs. 0.1%), MI (0.8% vs.0.6%), stent thrombosis (0.1% vs. 0.2%), ischemic stroke (0.4% vs. 0.2%), and major bleeding (0.1% vs. 0.1%). The rate of net adverse clinical events was 1.4% with DAPT beyond 12 months and 1.1% with 12-month DAPT ( p = 0.466). Conclusions: DAPT beyond 12 months, as compared with 12-month DAPT, in real-world patients with acute MI treated predominantly with second-generation DES did not reduce the risk of MACCE. The rates of major bleeding and net adverse clinical events did not differ significantly between the 2 treatments.-
dc.description.statementofresponsibilityprohibition-
dc.publisherSchool of Medicine (의과대학)-
dc.rightsBY_NC_ND-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.0/kr-
dc.subjectAntiplatelet agents-
dc.subjectDrug-eluting stents-
dc.subjectMyocardial infarction-
dc.titleDual Antiplatelet Therapy Beyond 12 Months Versus for 12 Months After Drug-Eluting Stents for Acute Myocardial Infarction-
dc.typeArticle-
dc.contributor.localauthor허승호-
dc.contributor.alternativelocalauthorHur, Seung Ho-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.citation.volume75-
dc.citation.number1-
dc.citation.startpage66-
dc.citation.titleJournal of cardiology-
dc.citation.endpage73-
dc.identifier.doi10.1016/j.jjcc.2019.06.006-
dc.identifier.urlhttps://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0914508719301765-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE